Patent: 9,487,810
✉ Email this page to a colleague
Summary for Patent: 9,487,810
Title: | Methods of cell culture |
Abstract: | Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described. |
Inventor(s): | Prentice; Holly (Carlisle, MA), Tijani; Rasheed (Haverhill, MA), Belongia; Brett (North Andover, MA) |
Assignee: | Momenta Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 14/587,340 |
Patent Claims: | see list of patent claims |
Details for Patent 9,487,810
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Centocor Ortho Biotech Products, L.p. | ORTHOCLONE OKT3 | muromanab-cd3 | Injection | 103463 | 09/14/1992 | ⤷ Try a Trial | 2033-03-14 |
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | ⤷ Try a Trial | 2033-03-14 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-03-14 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2033-03-14 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2033-03-14 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2033-03-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |